Dose immunogenicity study of a plant-produced influenza virus-like particle vaccine in layer hens

Abolnik, Célia; Smith, Tanja; Wandrag, Daniel B.R.; Murphy, Mark-Anthony; Rautenbach, Marizel; Olibile, Olebile; O’Kennedy, Martha M.

doi:10.1016/j.heliyon.2022.e09804

Cited by 8 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11,12 Rapid synthesis of many doses is possible once a field virus has been genetically sequenced, and no live virus is required. 13 The haemagglutinin (HA) protein expressed on a virus-like particle (VLP) is highly ordered in a dense array, similar to a live virus, which stimulates a strong cellular and humoral response. 14 The absence of internal viral proteins, such as nucleoprotein (NP), allows for DIVA using standard ELISA tests.…”

Section: Introductionmentioning

confidence: 99%

“…In vitro‐produced recombinant antigen vaccines, synthesised in plant leaf tissue, insect or bacterial cells, offer alternatives to conventional inactivated vaccines 11,12 . Rapid synthesis of many doses is possible once a field virus has been genetically sequenced, and no live virus is required 13 . The haemagglutinin (HA) protein expressed on a virus‐like particle (VLP) is highly ordered in a dense array, similar to a live virus, which stimulates a strong cellular and humoral response 14 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination of African penguins (Spheniscus demersus) against high‐pathogenicity avian influenza

Roberts,

Abernethy,

Roberts

et al. 2023

Veterinary Record

Self Cite

View full text Add to dashboard Cite

BackgroundHigh‐pathogenicity avian influenza (HPAI) has become a conservation threat to wild birds. Therefore, suitable vaccine technology and practical application methods require investigation.MethodsTwenty‐four African penguins (Spheniscus demersus) were vaccinated with either a conventional inactivated clade 2.3.4.4b H5N8 HPAI whole virus or a tobacco leaf‐produced H5 haemagglutinin‐based virus‐like particle (VLP). Six birds received a second dose of the inactivated vaccine. Antibody responses were assessed and compared by employing haemagglutination inhibition tests.ResultsA second dose of inactivated vaccine was required to induce antibody titres above the level required to suppress virus shedding, while a single dose of VLP vaccine produced these levels by day 14, and one bird still had antibodies on day 430.LimitationsBacterial contamination of the VLP vaccine limited the monitoring period and sample size in that treatment group, and it was not possible to perform a challenge study with field virus.ConclusionVLP vaccines offer a more practical option than inactivated whole viruses, especially in logistically challenging situations involving wild birds.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Vaccination of African penguins (Spheniscus demersus) against high‐pathogenicity avian influenza

Roberts,

Abernethy,

Roberts

et al. 2023

Veterinary Record

Self Cite

View full text Add to dashboard Cite

show abstract

“…Virus-like particles (VLP) show high plasticity and scalability to develop multiple subtypes of influenza vaccines, including H5 [ 8 ], H6 [ 9 ], H7 [ 10 ], and H9 [ 11 ] subtypes, which are produced in various expression systems, such as insect cell-baculovirus [ 10 ], plant cells [ 12 ], and mammalian cells [ 13 ]. Furthermore, the innocuous VLP retains the structural and immunological properties of a native virus.…”

Section: Introductionmentioning

confidence: 99%

A single immunization with H5N1 virus-like particle vaccine protects chickens against divergent H5N1 influenza viruses and vaccine efficacy is determined by adjuvant and dosage

Kong,

He,

Wang

et al. 2023

Emerging Microbes & Infections

View full text Add to dashboard Cite

The H5N1 subtype highly pathogenic avian influenza virus (HPAIV) reveals high variability and threatens poultry production and public health. To prevent the spread of H5N1 HPAIV, we developed an H5N1 virus-like particle (VLP) vaccine based on the insect cell-baculovirus expression system. Single immunization of the H5N1 VLP vaccines induced high levels of HI antibody titres and provided effective protection against homologous virus challenge comparable to the commercial inactivated vaccine. Meanwhile, we assessed the relative efﬁcacy of different adjuvants by carrying out a head-to-head comparison of the adjuvants ISA 201 and ISA 71 and evaluated whether the two adjuvants could induce broadly protective immunity. The ISA 71 adjuvanted vaccine induced significantly higher levels of Th1 and Th2 immune responses and provided superior cross-protection against antigenically divergent H5N1 virus challenge than the ISA 201 adjuvanted vaccine. Importantly, increasing the vaccine dose could further enhance the cross-protective efficacy of H5N1 VLP vaccine and confer completely sterilizing protection against antigenically divergent H5N1 virus challenge, which was mediated by neutralizing antibodies. Our results suggest that the H5N1 VLP vaccine can provide broad-spectrum protection against divergent H5N1 influenza viruses as determined by adjuvant and vaccine dose.

show abstract

Bioeconomy for Sustainable Biomaterials and Bioproduct Development

Babu,

Pancholi,

Rao

et al. 2024

Bioeconomy for Sustainability

View full text Add to dashboard Cite

Dose immunogenicity study of a plant-produced influenza virus-like particle vaccine in layer hens

Cited by 8 publications

References 40 publications

Vaccination of African penguins (Spheniscus demersus) against high‐pathogenicity avian influenza

Vaccination of African penguins (Spheniscus demersus) against high‐pathogenicity avian influenza

A single immunization with H5N1 virus-like particle vaccine protects chickens against divergent H5N1 influenza viruses and vaccine efficacy is determined by adjuvant and dosage

Bioeconomy for Sustainable Biomaterials and Bioproduct Development

Contact Info

Product

Resources

About